Introduction {#Sec1}
============

Worldwide, pneumococcal disease is associated with significant clinical and economic burden on healthcare systems and the society. *Streptococcus pneumoniae* (*Sp*) is responsible for both invasive and non-invasive respiratory infections causing diseases such as bacteremia, meningitis, pneumonia and acute otitis media (AOM) \[[@CR1]\]. Vaccination with pneumococcal conjugate vaccines (PCVs) remains the cornerstone in preventing pneumococcal disease. Over the last decade, pneumococcal vaccines have been widely implemented in childhood universal mass immunization programs worldwide \[[@CR1]--[@CR7]\].

In Japan, the 7-valent PCV (PCV-7, *Prevnar/Prevenar*™, Pfizer, Pearl River, NY, USA) was officially recommended for use in children aged \<5 years in 2010. PCV-7 was incorporated into the routine national vaccination schedule for children in April 2013 and eventually replaced by the 13-valent PCV (PCV-13, *Prevenar 13*™, Pfizer, Pearl River, NY, USA) on November 1, 2013. Local surveillance studies have shown a marked decrease in the prevalence of invasive pneumococcal infections in children aged \<5 years {2011--2013 versus 2008--2010 as reflected by a 51% reduction with an associated incidence rate ratio (IRR) of 0.49 \[95% confidence interval (CI) 0.37--0.63, *p* \< 0.0001\] \[[@CR7]\]. In another study, it was reported that the incidence of meningitis and bacteremia attributable to vaccine serotypes substantially dropped from 73.3 to 14.7% in the period 2010--2013} \[[@CR8]\]. Ihara et al. \[[@CR9]\] estimated that incidence rates per 100,000 in children aged \<5 years during 2012 (versus 2008--2010) for meningitis and bacteremia changed from 2.8 to 0.8 (IRR 0.27; *p* \< 0.0001) and 22.2 to 10.6 (IRR 0.48; *p* \< 0.0001), respectively. Due to these dramatic declines in disease burden due to PCV-7 types, non-PCV-7 serotype strains now constitute a predominant cause of residual pneumococcal disease burden in Japanese children \[[@CR7]--[@CR9]\]. A review of epidemiology of pediatric infections in Japan from 1990 onward shows that in addition to pneumococci, another respiratory pathogen, non-typeable *Haemophilus influenzae* (NT*Hi*), causes significant morbidity in pediatric AOM, and, to a lesser extent, plays a role in lower respiratory diseases such as pneumonia \[[@CR10], [@CR11]\]. NT*Hi* has been also reported as an infrequent cause of invasive disease \[[@CR12]\].

Bacterial infections often lead to high rates of prescription and antibiotic use \[[@CR1], [@CR13]\]. This is specifically the case with highly prevalent AOM which is recognized as a leading indication for the prescription of antibiotics to infants \[[@CR13]\]. In Japan, resistance to commonly used antibiotics such as penicillins, macrolides and cephalosporins is increasingly observed for both *Sp* serotypes and NT*Hi*, thereby rendering treatment of such infections difficult \[[@CR8], [@CR12], [@CR14], [@CR15]\]. In the global context including Japan \[[@CR8], [@CR16]\], prevention of pneumococcal disease by vaccination could play a significant role in controlling the evolution of resistance which is essential from a health policy point of view.

Both PCV-13 and the 10-valent pneumococcal non-typeable *Haemophilus influenzae* protein D conjugate vaccine (PHiD-CV, *Synflorix*™, GlaxoSmithKline Biologicals SA, Rixensart, Belgium) have a broader serotype coverage than PCV-7. PHiD-CV covers three additional *Sp* serotypes (I, 5 and 7F) compared with PCV-7. This vaccine was designed to target *Sp* and potentially NT*Hi* infections due to the use of NT*Hi*-derived protein D as a carrier protein for the majority of its conjugates \[[@CR17], [@CR18]\]. Compared to PHiD-CV, PCV-13 contains three additional *Sp* serotypes (3, 6A and 19A), but clinical evidence shows that PHiD-CV offers protection for the cross-reactive *Sp* serotypes 6A \[[@CR17], [@CR19]\] and 19A \[[@CR19]--[@CR21]\]. To date, there is no conclusive evidence that PCV-13 prevents invasive pneumococcal disease (IPD), AOM or pneumonia due to serotype 3 \[[@CR22], [@CR23]\].

The choice of PCV for national immunization programs is usually determined by a combination of multiple factors which often include, but may not be limited to, pathogen epidemiology prevalent in the target group locally, vaccine formulation, vaccine supply and cost-effectiveness considerations. It is, therefore, important to assess the potential benefits that the new generation vaccines, PCV-13 or PHiD-CV, may offer in epidemiological and economic terms to ensure efficient allocation of healthcare resources based on evidence-driven trade-offs of competing healthcare options. The performed cost-effectiveness evaluation presented in this paper aims to estimate and compare the potential impact of two childhood universal immunization strategies: routine vaccination of infants with PHiD-CV and PCV-13, the latter of which is currently recommended for routine immunization of infants in Japan.

Materials and Methods {#Sec2}
=====================

Model Overview {#Sec3}
--------------

A previously published Markov model \[[@CR24], [@CR25]\] was used to simulate the impact of pneumococcal vaccination on the incidence of *Sp* IPD, pneumonia and AOM, as well as NT*Hi*-AOM within a Japanese birth cohort (*n* = 1,042,000 new-born) in terms of resource use, cost implications and quality-adjusted life-year (QALY) losses. Cost-effectiveness was evaluated adopting the healthcare provider and societal perspectives. The model was used to compare 3 + 1 regimens of PHiD-CV and PCV-13 with vaccine doses administered at 2, 3, 4 and 13 months of life.

The basic model construct is visualized in Fig. [1](#Fig1){ref-type="fig"}. Individuals were followed in the age-stratified model over a time horizon of 5 years with a cycle length of 1 month. During each monthly cycle, the probability of an individual entering a specific health state is governed by age-specific *Sp* and NT*Hi*-AOM incidence rates and applicable vaccine efficacy (VE) levels. These transition probabilities determine hospitalization rates and frequency of medical visits in conjunction with the respective diseases considered in the model. To the respective disease conditions, unit costs and disease-specific disutilities were further added. In each cycle of the model, cost consequences and QALYs were estimated so that costs and QALY losses accumulated until the 5 year time horizon and converted into a corresponding incremental cost-effectiveness ratio (ICER) expressed in terms of costs per QALY gained.Fig. 1Model structure. *AOM* acute otitis media, *B* bacteraemia, *M* meningitis, *PCV-13* 13-valent pneumococcal conjugate vaccine, *PHiD-CV* 10-valent pneumococcal non-typeable *Haemophilus influenzae* protein D conjugate vaccine, *P* pneumonia

Demographics and Epidemiological Data {#Sec4}
-------------------------------------

Annual number of births and age-specific mortality rates were obtained from the "Estimation of population" (2013) \[[@CR26]\] and the "Abridged life tables" (2012) \[[@CR27]\], respectively, available in the Official Statistics of Japan (e-Stat) database. Epidemiological data used in the model are provided in Table [1](#Tab1){ref-type="table"}. Age-specific incidence rates for IPD, hospitalized all-cause pneumonia and AOM were taken from locally available databases and published literature \[[@CR9], [@CR12], [@CR14], [@CR28]\]. The incidence rate for non-hospitalized all-cause pneumonia was derived by subtracting the number of pneumonia-related hospital admissions from the total number of pneumonia cases as provided by the "Patient survey" \[[@CR29]\]. The frequency of meningitis sequelae was estimated from Kamiya et al. \[[@CR28]\] and Iwata et al. \[[@CR30]\]. The frequency of myringotomy/tympanostomy tube placement (TTP) procedures was obtained from a retrospective survey (Table [1](#Tab1){ref-type="table"}; for additional details on the retrospective survey see Appendix [1](#Sec15){ref-type="sec"}, Table [6](#Tab6){ref-type="table"}).Table 1Model input for base case analysis: epidemiological data*AOM* acute otitis media, *CFR* case--fatality ratio, *IPD* invasive pneumococcal disease, *NTHi* non-typeable *Haemophilus influenzae*, *Sp* *Streptococcus pneumoniae*, *TTP* tympanostomy tube placement

Serotype distributions for IPD and AOM were obtained from published reports addressing the point in time when PCV-13 was introduced in Japan \[[@CR9], [@CR12]\]. The proportion of AOM cases due to *Sp* or NT*Hi* was estimated by calculating the ratio of confirmed number of *Sp* or NT*Hi*-related cases and the total number of pathogen-confirmed cases (Table [1](#Tab1){ref-type="table"}).

Direct Economic Burden, Resource Use and Quality of Life {#Sec5}
--------------------------------------------------------

Retrospective database analyses were performed involving two commercially available Japanese claims databases. The EBM provider developed by Medical Data Vision Co., Ltd (MDV-EBM provider) and Japan Medical Data Centre Claims Database (JMDC-CDB) were used to gather information on resource use and costs for IPD, pneumonia and AOM, respectively. MDV-EBM provider is a hospital-based database which covers approximately five million patients and contains medical account data (inpatient and outpatient) with detailed inpatient information of patients of all ages. JMDC-CDB is a health insurance claims database which covers approximately 1% of Japanese population aged \<75 years and contains data on inpatient, outpatient and pharmacy expenditure for employees and their family members in contracted health insurance societies. The database analyses provided estimates for the averages of the treatment cost per acute episode for each disease, the number of admission days and the number of outpatient visits. The average treatment cost per acute episode was calculated based on the medical fee point for each procedure and National Health Insurance drug prices at the time of the medical treatment (Appendix [1](#Sec15){ref-type="sec"}, Table [7](#Tab7){ref-type="table"}).

Indirect costs (2013) were evaluated as lost wages for parents providing care. The productivity loss per acute disease episode was equivalent to the number of work days lost estimated by adding up the number of hospital admission days and outpatient visits for the child (1 visit = 0.5 day lost). Daily wages were estimated on the basis of average annual salary of individuals aged 18--49 years \[3,330,415.73 Japanese yen (JPY)\] obtained from the "Basic survey of wage structure" (2013) \[[@CR31]\] and "Survey of Labour force" \[[@CR32]\]. Time lost from work for parents of sick children for each of the disease outcomes is provided in Table [2](#Tab2){ref-type="table"}.Table 2Model input for base case analysis: cost dataNo. of acute episodesAverage treatment cost per acute episode \[JPY\]Average cost per acute episode Meningitis (hospitalized)57767,447 Bacteremia (hospitalized)137340,905 All-cause pneumonia (hospitalized)440286,209 All-cause pneumonia (outpatient)75916,998 AOM with myringotomy19345,853 AOM without myringotomy2,74218,185Average annual costs for long-term sequelae \[JPY\] Neurological sequelae452,260 Hearing loss79,311Work loss for parentsNo. of admission daysNo. of visitsAverage time lost from work (days)^a^Meningitis---acute episode13.81.514.6Bacteremia (hospitalized)7.21.47.9All-cause pneumonia (hospitalized)6.11.97.1All-cause pneumonia (outpatient)NA1.91.0AOM with myringotomy/TTP0.09.54.8AOM without myringotomy0.04.32.2*AOM* acute otitis media, *JPY* Japanese yen, *TTP* tympanostomy tube placement, *NA* not applicable^a^Estimated by adding up the number of hospital admission days and the number of outpatient visits (1 visit = 0.5 day lost)

Two types of utility values were used in the model. Normative utility values were assumed to be at the maximum due to the short time horizon considered in the analysis. Disutility values for the disease conditions were obtained from sources provided in Table [3](#Tab3){ref-type="table"}.Table 3Model input for base case analysis: disutilitiesDisease conditionDisutility valueReference/assumptionDisutility per episode (short-term) Meningitis (hospitalized)0.023Bennett et al. \[[@CR55]\] Bacteremia (hospitalized)0.008 Pneumonia (hospitalized)0.008Assumed to be the same as for hospitalized bacteremia Pneumonia (outpatient)0.006Bennett et al. \[[@CR55]\] AOM without myringotomy0.005Oh et al. \[[@CR56]\] AOM with myringotomy/TTP procedures0.005Assumed to be the same as for AOM without myringotomyDisutility per year (long term) Neurological sequelae from meningitis0.400Morrow et al. \[[@CR57]\] Hearing loss from meningitis0.200Morrow et al. \[[@CR57]\], Cheng et al. \[[@CR58]\]*AOM* acute otitis media, *TTP* tympanostomy tube placement

Vaccine Efficacy, Coverage and Costs {#Sec6}
------------------------------------

The time course of protection conferred by vaccination was modeled in children of ages of 2 months until 5 years, with a ramp-up phase coinciding with the course of vaccine dosing from the age of 2 months until 13 months and a full efficacy phase from the age of 13 months up until 5 years. In the ramp-up phase the level of protection established with the sequential doses was assumed to be 50, 90, 90 and 100% following the first three vaccine doses and booster vaccination, respectively. VE estimates used in this analysis were obtained from published clinical trials and post-marketing studies and validated by a panel of experts (Table [4](#Tab4){ref-type="table"}).Table 4Model input for base case analysis: vaccine efficacyVE% (95% CI)Reference/assumptionPHiD-CVPCV-13IPD 10 common serotypes for PHiD-CV and PCV-1394.7% (87--100)94.7% (87--100)Whitney et al. \[[@CR19]\] Serotype 30.0% (0--0)0.0% (0--89)Expert opinion\
Moore et al. \[[@CR33]\] Serotype 6A76.0% (39--90)94.7% (87--100)Whitney et al. \[[@CR19]\] Serotype 19A82.2% (11--96)94.7% (87--100)Domingues et al. \[[@CR20]\]\
Whitney et al. \[[@CR19]\]Pneumonia Hospitalization23.4% (9--36)23.4% (9--36)Tregnaghi et al. \[[@CR18]\] Non-hospitalization7.3% (2--12)7.3% (2--12)Tregnaghi et al. \[[@CR18]\]AOM without myringotomy 10 common serotypes for PHiD-CV and PCV-1369.9% (30--87)69.9% (30--87)Tregnaghi et al. \[[@CR18]\] Serotype 30.0% (0--0)0.0% (0--0)Expert opinion Serotype 6A63.7% (−14--88)69.9% (30--87)Prymula et al. \[[@CR17]\]\
Tregnaghi et al. \[[@CR18]\] Serotype 19A60.7% (8--71)69.9% (30--87)Expert opinion\
Tregnaghi et al. \[[@CR18]\] Others0.0% (−33--15)0.0% (−33--1)Tregnaghi et al. \[[@CR18]\]\
Prymula et al. \[[@CR17]\]\
Eskola et al. \[[@CR39]\]\
Expert opinion NT*Hi*21.5% (0--35)0.0% (−11--8)Tregnaghi et al. \[[@CR18]\]\
Prymula et al. \[[@CR17]\]\
Eskola et al. \[[@CR39]\]\
Expert opinionAOM with myringotomy/TTP Myringotomy/TTP40.4% (−9--75)27.0% (−14--50)Fireman et al. \[[@CR40]\]\
Palmu et al. \[[@CR41]\]The 95% CI values were used as the boundary in the sensitivity analyses*AOM* acute otitis media, *PCV-13* 13-valent pneumococcal conjugate vaccine, *PHiD-CV* 10-valent pneumococcal NT*Hi* protein D conjugate vaccine, *TTP* tympanostomy tube placement

The impact of vaccination on IPD disease burden was calculated by applying serotype-specific VE to the respective *Sp* serotypes causing disease in the target group for vaccination. Serotype-specific VE data were extrapolated from available efficacy and effectiveness PCV trials. It is assumed that PHiD-CV and PCV-13 have the same efficacy for the ten common serotypes equal to the average VE of the PCV-7 serotypes, as reported by Whitney et al. \[[@CR19]\]. Although serotypes 6A and 19A are not contained in the PHiD-CV vaccine, these serotypes belong functionally to the same serogroups as serotypes 6B and 19F, respectively, which are covered by the PHiD-CV vaccine. Protection conferred by PHiD-CV against cross-reactive serotypes 6A not contained in PHiD-CV was set at 76% in the light of similar antibody responses elicited by PCV-7 and PHiD-CV \[[@CR19]\]. For serotype 19A, VE was set at 82.2% as observed for PHiD-CV in a case--control study \[[@CR19], [@CR20]\]. To date, there is no conclusive evidence that PCV-13 prevents serotype 3 disease \[[@CR33]\] and, therefore, VE was assumed to be 0.0% in the base case analysis.

The model uses VE against World Health Organization (WHO)-defined X-ray-confirmed community-acquired pneumonia (CAP) (WHO-CAP) as a surrogate measure of efficacy against hospitalization for pneumonia. VE of PCVs, including PHiD-CV against WHO-CAP and suspected CAP, has been assessed in several large-scale, randomized, controlled efficacy trials, conducted in different settings \[[@CR18], [@CR34]--[@CR37]\]. In these trials, WHO-CAP and clinically suspected CAP constituted the efficacy end points. VE in terms of reduction in hospitalization and outpatient consultation was in the ranges of 20--35% and 6--7%, respectively, based on defined end points not discriminating between causative pathogens \[[@CR18], [@CR34]--[@CR37]\]. In the absence of PCV-13 estimates, and taking into account that available pneumonia efficacy data cannot easily predict the impact of a PCV on pneumonia by relying on the number of serotypes or support the notion that increasing numbers of serotypes beyond PCV-7 will result in a detectable increase in protection against pneumonia \[[@CR38]\], the Clinical Otitis Media & Pneumonia Study (COMPAS, ClinicalTrials.gov Identifier: NCT00466947) efficacy estimates against WHO-CAP (23.4%) and suspected CAP (7.3%) for PHiD-CV were applied to PCV-13 as well \[[@CR18]\].

VE against AOM without myringotomy/TTP procedures was ascertained based on *Sp* and NT*Hi* prevalence. VE against *Sp* vaccine serotypes was assumed to be 69.9% for PHiD-CV \[[@CR18]\]. Similar to VE estimation for IPD, partial protection efficacy levels of 63.7% against 6A \[[@CR17]\] and 60.7% against serotype 19A were assumed for PHiD-CV. In the base case analysis, the same VE was assumed for the PHiD-CV serotypes in PCV-13 for which AOM-related efficacy estimates were not available. The same assumption was also used for the additional PCV-13 serotypes except for serotype 3 (Table [4](#Tab4){ref-type="table"}). VE against serotype 3 was assumed to be 0.0% for both vaccines, as PHiD-CV does not include serotype 3 and PCV-13 effectiveness against serotype 3 is not confirmed. Although PCV-7 VE against *Sp* non-vaccine types and NT*Hi* has been reported as −33% and −11%, respectively (FIN-OM study \[[@CR39]\], ClinicalTrials.gov Identifier: NCT00378417), we made conservative assumptions of 0.0%. VE against *Sp* non-vaccine type AOM was assumed to be 0.0% for both vaccines (based on COMPAS for PHiD-CV \[[@CR18]\]). VE against NT*Hi*-AOM was assumed to be 21.5% and 0.0% for PHiD-CV and PCV-13, respectively \[[@CR17], [@CR18], [@CR39]\]. Reduction in myringotomy/TTP was estimated on the basis of PCV-7 efficacy obtained from a Kaiser Permanente study \[[@CR40]\] and the FinOM study \[[@CR41]\]. These reports indicate low VE against TTP at high incidences of TTP. This relationship was modeled by extrapolating PCV-13 and PHiD-CV VE from that of PCV-7. Extrapolated VE estimates were well in agreement with the findings of the FinIP study \[[@CR42]\]. The likely higher efficacy of PHiD-CV compared to PCV-13 for AOM is reflected in the estimates of VE against myringotomy/TTP (Table [4](#Tab4){ref-type="table"}).

For simplicity, vaccination coverage was assumed as 100% in the base case. Price parity of 7,776 JPY was assumed for both PHiD-CV and PCV-13. The administration cost per vaccine dose was assumed to be 4,212 JPY \[[@CR43]\].

Analyses {#Sec7}
--------

Under base case assumptions, numbers of deaths and cases of IPD, all-cause pneumonia (hospitalized and non-hospitalized), and AOM (with and without myringotomy/TTP procedures) were estimated for both vaccines. The direct costs, including vaccination and treatment, and the indirect costs for each disease outcome were estimated. All costs are reported in JPY. The effects between the two vaccination strategies are reported as QALYs and life-years (LYs) gained, which are related to the defined health outcome that was determined. The ICER was estimated. A 3.0% discount rate was used for both cost and outcomes to allow a proper assessment of the benefit from the start of vaccination.

In addition to the base case analysis, several scenarios were modeled based on local interest wherein hypothetical considerations and different combinations of parameters were used to populate the model to examine their potential impact on cost and effect outcomes (Appendix [1](#Sec15){ref-type="sec"}). To account for uncertainty in the key model assumptions, two types of sensitivity analyses were performed. A one-way sensitivity analysis was done in which model parameters such as VE, disease epidemiology and management were varied within a pre-specified range of ±20% if 95% CI was unavailable. A probabilistic sensitivity analysis (PSA) was performed by sampling simultaneously, from probability distributions linked to VE (log-normal distribution), disease incidence (beta distribution), disutility values (beta distribution) and costs (triangular distribution). An ICER below 5,000,000 (5 million) JPY per QALY gained was considered cost-effective for Japan \[[@CR44]\]. All the analyses were done using Microsoft *Excel*™ 2007/2010 (Microsoft Corporation, Washington, USA).

Trademark Disclosure {#Sec8}
--------------------

*Synflorix* is a trademark of the GSK group of companies, *Prevnar*/*Prevenar* is a trademark of Wyeth/Pfizer and *Prevnar13* is a trademark of Pfizer.

Compliance with Ethics Guidelines {#Sec9}
---------------------------------

This article does not contain any new studies with human or animal subjects performed by any of the authors. Where applicable, data were obtained from previously conducted studies.

Results {#Sec10}
=======

Base Case: Impact of Vaccination on Disease Burden and Cost-Effectiveness {#Sec11}
-------------------------------------------------------------------------

In a birth cohort of 1,042,000 newborn in Japan (2013), model projections indicate that PCV-13 and PHiD-CV were expected to provide equivalent impact in the prevention of deaths caused by IPD and all-cause pneumonia. While the estimated impact of PHiD-CV and PCV-13 were broadly similar for pneumococcal meningitis and bacteremia, and all-cause pneumonia, the model showed that PHiD-CV was expected to prevent a significantly larger number of AOM cases (92,467 AOM episodes) compared to PCV-13 (Table [5](#Tab5){ref-type="table"}).Table 5Model outcomes for base case analysisPHiD-CVPCV-13Difference (PHiD-CV-PCV-13)Disease-related outcomes Deaths due to IPDs, all-cause pneumonia and AOM66660 Cases of pneumococcal meningitis24231 Cases of pneumococcal bacteremia28626818 Cases of all-cause pneumonia479,841479,8410 Cases of AOM1,228,9711,321,438−92,467 Cases of meningitis sequelae440Economic outcomes \[JPY\]Direct costs (undiscounted) Vaccination49,916,940,48849,916,940,845−357 Pneumococcal meningitis18,258,44717,305,345953,102 Meningitis sequelae7,341,9336,988,325353,608 Pneumococcal bacteremia97,762,04891,511,9446,250,104 All-cause pneumonia27,229,316,26827,229,317,920−1,652 AOM24,033,839,82026,066,680,756−2,032,840,936Indirect costs Wages lost (acute episode)34,436,663,52536,591,103,326−2,154,439,801Cost-effectiveness outcomes (undiscounted) Total direct costs (JPY)101,303,459,004103,328,745,135−2,025,286,132 Total direct and indirect costs (JPY)135,740,122,528139,919,848,461−4,179,725,932 Total LYs gained5,197,5215,197,5220 Total QALYs gained5,188,3475,187,885462 ICER (healthcare provider perspective)----Dominant^a^ ICER (societal perspective)----Dominant^a^Cost-effectiveness outcomes (discounted) Total direct costs (JPY)97,339,123,66599,237,387,104−1,898,263,439 Total direct and indirect costs (JPY)129,652,473,264133,570,122,617−3,917,649,353 Total LYs gained4,837,7754,837,7750 Total QALYs gained4,829,1754,828,742433 ICER (healthcare provider perspective)----Dominant^a^ ICER (societal perspective)----Dominant^a^*AOM* acute otitis media, *JPY* Japanese yen, *ICER* incremental cost-effectiveness ratio, *IPD* invasive pneumococcal disease, *LY* life-year, *PCV-13* 13-valent pneumococcal conjugate vaccine, *PHiD-CV* 10-valent pneumococcal non-typeable *Haemophilus influenzae* protein D conjugate vaccine, *QALY* quality-adjusted life-years^a^PHiD-CV is dominant because it exhibits both lower costs and higher number of QALYs (effectiveness) compared to PCV-13

By assuming price parity for both PHiD-CV and PCV-13, a vaccination program with PCV-13 is shown to generate marginal cost savings for both meningitis and bacteremia; while PHiD-CV vaccination was expected to save an additional 1.9 billion JPY and 2.0 billion JPY in direct costs and indirect costs (undiscounted), respectively. The aggregate cost savings of 1.9 (direct costs, discounted) and 3.9 billion JPY (direct and indirect costs, discounted) with PHiD-CV were due to a reduction in AOM-related cases and myringotomy/TTP procedures resulting in a QALY gain of 433 (462 undiscounted) compared to PCV-13. Cost consequences and QALYs gain translated into ICERs of −4.4 million JPY and −9.1 million JPY per QALY gained for the provider and societal perspectives, thereby showing dominance of PHiD-CV over PCV-13 in the base case analysis (Table [5](#Tab5){ref-type="table"}).

Scenario and Sensitivity Analysis {#Sec12}
---------------------------------

For most of the modeled scenarios, PHiD-CV vaccination, in comparison to PCV-13, is expected to generate larger QALYs gains and lower costs from both the healthcare provider and societal perspectives, which translated into dominance of vaccination with PHiD-CV over PCV-13 (Fig. [2](#Fig2){ref-type="fig"}). One-way sensitivity analyses substantiated AOM/TTP-related parameters as consistent influential drivers of model outcome. Sensitivity analyses also demonstrated the robustness of the base case model outcome to changes in key model parameters and assumptions. Specifically, the one-way sensitivity analyses showed that the ICERs were most sensitive to PHiD-CV efficacy against NT*Hi*-AOM, percentage reduction in myringotomy/TTP procedures and changes in other AOM-related parameters from both the provider and societal perspectives. Despite varying these parameters, PHiD-CV vaccination was either cost saving or cost-effective compared to PCV-13 vaccination (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Scenario analyses. **a** Healthcare provider perspective, **b** societal perspective. *1* No protection for PHiD-CV against cross-reactive types 6A and 19A; *2* no efficacy of PHiD-CV against NT*Hi*-AOM; *3* decreased VE for reduction of myringotomy; *4* no efficacy of PHiD-CV against NT*Hi-*AOM and decreased VE for reduction of myringotomy; *5* decreased efficacy of PCV-13 against *Sp*-AOM; *6* decreased VE for reduction of myringotomy; *7* decreased efficacy of PCV-13 against *Sp*-AOM and decreased VE for reduction of myringotomy. *AOM* acute otitis media, *JPY* Japanese yen, *PCV-13* 13-valent pneumococcal conjugate vaccine, *PHiD-CV* 10-valent pneumococcal non-typeable *Haemophilus influenzae* protein D conjugate vaccine, *QALY* quality-adjusted life-years, *Sp* *Streptococcus pneumonia*Fig. 3One-way sensitivity analyses. **a** Healthcare provider perspective, **b** societal perspective. *AOM* acute otitis media, *JPY* Japanese yen, *NTHi* non-typeable *Haemophilus influenza*, *nVT* non-vaccine type, *PCV-13* 13-valent pneumococcal conjugate vaccine, *PHiD-CV* 10-valent pneumococcal non-typeable *Haemophilus influenzae* protein D conjugate vaccine, *QALY* quality-adjusted life-years, *Sp* *Streptococcus pneumoniae*, *VT* vaccine type

In the PSA, vaccination PHiD-CV is shown to dominate PCV-13 in terms of QALYs gained and cost savings (89% and 90% of the simulations in provider and societal perspectives, respectively). In contrast, only 4% of the simulations indicated that vaccination with PCV-13 was expected to dominate PHiD-CV in both perspectives. The probability that PHiD-CV vaccination was cost-effective compared to PCV-13 vaccination was estimated to be 93% from both perspectives (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Probabilistic sensitivity analysis. **a** Healthcare provider perspective, **b** societal perspective. *JPY* Japanese yen, *QALY* quality-adjusted life-years, *filled square* point estimate of base case analysis, the inclination of the line passing a point (0, 0) represents the cost-effectiveness threshold for Japan (5 million JPY per QALY gained)

Discussion {#Sec13}
==========

A recent study indicates that both, the disease burden and costs associated with highly prevalent AOM outweigh IPD due to the high volume of outpatient consultations, myringotomy/TTP procedures and utilization of antibiotics \[[@CR45]\]. A vaccine that confers significant protection against AOM and the associated frequent use of antibiotics could be advantageous in settings with highly prevalent AOM disease. PHiD-CV may help in the control of NT*Hi*-related AOM in addition to *Sp*-related AOM \[[@CR17], [@CR18], [@CR40], [@CR45]--[@CR49]\].

The potential impact of PHiD-CV and PCV-13 on IPD and AOM incidence was compared in children aged \<5 years using a previously published age-stratified Markov model \[[@CR24], [@CR25]\] that was populated with epidemiological, resource use and cost data specific for Japan. The model findings demonstrate a similar impact on overall IPD outcomes with either vaccine. In terms of IPD incidence and associated deaths, a similar impact was predicted for either of the formulations, in line with likely marginal, if any at all, differences in protection reflected by serotype-specific VE for vaccine and vaccine-related serotypes 6A \[[@CR19]\] and 19A \[[@CR19]--[@CR21]\]. Similarly, identical VE against pneumonia was assumed which resulted in equivalent impact on pneumonia-related outcomes. However, PHiD-CV is projected to have a larger public health and economic impact owing to the high disease incidence of AOM in Japan \[[@CR12]\] and its likely larger effects against this clinical syndrome compared to PCV-13. Although, a large body of evidence, including both preclinical and clinical research, points to the potential NT*Hi*-related impact of PHiD-CV in AOM \[[@CR17], [@CR18], [@CR46], [@CR48], [@CR50]\], rather conservative assumptions have been made in this cost-effectiveness model with respect to the magnitude of its NT*Hi*-effect in AOM. Nonetheless, an incremental benefit with PHiD-CV over PCV-13 is observed for NT*Hi*-related AOM outcomes.

Given the current epidemiological landscape in Japan and our model findings regarding impact on disease outcomes, it is likely that childhood immunization with PHiD-CV in Japan will result in better cost-offsets and health gain compared to PCV-13. Under base case assumptions, PHiD-CV vaccination of infants is a cost-saving modality compared with PCV-13 vaccination from both the healthcare provider and societal perspectives. Sensitivity analyses showed that ICER was robust to changes in key model parameters and confirmed a consistent impact of AOM prevention on model outcome. The model outcome was driven by the incremental benefit of PHiD-CV in terms of preventing highly prevalent AOM disease and myringotomy/TTP procedures. In the light of the publications of \[[@CR45]\] which has shown that PHiD-CV vaccination reduced the rates of antibiotic prescriptions in outpatient settings, one may therefore expect that the introduction of PHiD-CV in Japan will reduce the frequency of antibiotic use in conjunction with highly prevalent AOM and consequently likely contribute to the control of increasing antibiotic resistance of NT*Hi* bacteria in addition to *Sp* \[[@CR10], [@CR12]\].

While the cost-effectiveness profiles of different pneumococcal vaccination strategies in several countries have been previously described using similar tools such as Markov cohort models \[[@CR24], [@CR25]\], a direct comparison of results and, therefore, generalizability are limited due to the differences in the local epidemiology of the disease under investigation and healthcare systems specific to each country. Apart from generalizability, there are several study limitations that need to be addressed. Reliable epidemiological data such as incidence in individuals aged \>5 years are not available for Japan; hence, a time horizon of 5 years was used in the base case analysis. While waning of VE is usually assumed from 2 years after vaccination, however, due to the short time horizon this factor was not considered in the analysis. In addition, while productivity losses due to the treatment of acute disease were evaluated, productivity losses due to long-term sequelae were not estimated due to lack of data. The incidence of pneumonia was based on information for the time period prior to PCV-7 implementation due to limited data from post-PCV-7 vaccination implementation in Japan, implying that there is a need for up-to-date epidemiological data for future epidemiological and cost-effectiveness studies. In our analysis, herd protection was not assumed given that the analytical time horizon was restricted to child age cohorts. To our knowledge, the implications of herd protection have not been addressed in any of the cost-effectiveness analyses published for Japan \[[@CR51], [@CR52]\]. Previous studies have examined the potential magnitude of such indirect effects including herd protection and serotype replacement \[[@CR38]\]. The findings varied considerably, therefore providing the rationale for not including herd protection in the current model \[[@CR53]\]. To assess the true cost-effectiveness profiles of PCV vaccination modalities and explore sustainability of the selected PCV in Japan, it is suggested to investigate the importance of these factors in the overall impact of vaccination.

Conclusions {#Sec14}
===========

This cost-effectiveness analysis shows that a 3 + 1 universal childhood vaccination program using PHiD-CV, priced at parity with PCV-13, is expected to be cost saving compared to an identical vaccination program involving PCV-13, specifically in providing incremental benefits with AOM, translating into fewer cases of AOM and myringotomy/TTP procedures, as well as associated costs, both from healthcare provider and societal perspectives. Given the importance of pneumococcal serotype coverage and associated serotype-specific VE levels including protection against cross-reactive serotypes, modeling exercises accommodating these aspects adequately provide valuable insights into how these factors may play out in the context of local epidemiology. Nonetheless, it is important to continuously and actively monitor epidemiological changes effected by pneumococcal vaccination to inform future decision making and healthcare policy in Japan.
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See Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}.Table 6Retrospective surveyMeningitisBacteremiaAll-cause pneumoniaAOM^a^Data sourceMedical Data VisionMedical Data VisionMedical Data VisionJapan Medical Data CentreICD-10 diagnosis^b^G001: Pneumococcal meningitis\
G009: Bacterial meningitis\
G009: Acute bacterial meningitisA403: Sepsis due to *Sp*\
A419: Sepsis\
A499: BacteremiaJ13: Pneumonia due to *Sp*\
J14: Pneumonia due to *Haemophilus influenzae*\
J189: PneumoniaH660: Acute Suppurative otitis media\
H664: Suppurative otitis media\
H669: AOM\
H669: Otitis mediaAge\<5 years old\<5 years old\<5 years old\<5 years oldAnalysis periodApr 01, 2010--Mar 31, 2013Apr 01, 2010--Mar 31, 2013Apr 01, 2012--Mar 31, 2013Apr 01, 2012--Mar 31, 2013Department visitedAllAllIncluding pediatricsPediatrics or otorhino-laryngology*AOM* acute otitis media, *ICD-10* the international statistical classification of diseases and related health problems 10th revision^a^One episode was defined as a series of treatment with a visit interval of less than 1 month from the initial diagnosis. When the treatment was restarted after the visit interval of 1 month or more, it was regarded as a different episode^b^Codes have been used to extract cost informationTable 7Scenario analysesPHiD-CVPCV-13Scenario (1) Efficacy of IPDs6A and 19A: 0.0%Base case (2) Efficacy of NT*Hi-*AOM0.0%Base case (3) % reduction in myringotomy26.1%^a^Base case (4) = (2) + (3)NT*Hi-*AOM efficacy: 0.0%Base case% reduction in myringotomy: 26.1% (5) Efficacy of *Sp*-AOMBase caseCommon vaccine serotypes, 6A, and 19A: 57.0% (Eskola et al.) \[[@CR39]\] (6) % reduction in myringotomyBase case22.0%^b^ (7) = (5) + (6)Base caseCommon vaccine serotypes, 6A and 19A: 57.0%% reduction in myringotomy/TTP: 22.0%*AOM* acute otitis media, *IPD* invasive pneumococcal disease, *PCV-13* 13-valent pneumococcal conjugate vaccine, *PHiD-CV* 10-valent pneumococcal non-typeable *Haemophilus influenzae* protein D conjugate vaccine, *Sp Streptococcus pneumoniae*^a^Calculated value in case of no efficacy of PHiD-CV against NT*Hi-*AOM^b^Calculated value in case of the efficacy of PCV-13 against *Sp* vaccine serotype AOM taken from FIN-OM study \[[@CR39]\]
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